Market Closed -
OTC Markets
03:53:47 2024-07-12 pm EDT
|
5-day change
|
1st Jan Change
|
17.89
USD
|
+2.05%
|
|
-0.11%
|
-17.75%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,844
|
14,460
|
18,352
|
15,573
|
16,747
|
12,635
|
-
|
-
|
Enterprise Value (EV)
1 |
15,143
|
17,845
|
20,687
|
16,370
|
19,049
|
15,351
|
15,283
|
15,174
|
P/E ratio
|
22.2
x
|
27.5
x
|
14.1
x
|
10.9
x
|
24.5
x
|
25.6
x
|
22.7
x
|
19.5
x
|
Yield
|
3.1%
|
2.79%
|
2.37%
|
3.03%
|
2.92%
|
3.58%
|
3.64%
|
3.97%
|
Capitalization / Revenue
|
2.09
x
|
2.12
x
|
2.1
x
|
1.67
x
|
2.05
x
|
1.43
x
|
1.35
x
|
1.3
x
|
EV / Revenue
|
2.47
x
|
2.61
x
|
2.36
x
|
1.75
x
|
2.33
x
|
1.74
x
|
1.64
x
|
1.56
x
|
EV / EBITDA
|
14.3
x
|
12.5
x
|
8.08
x
|
5.78
x
|
11.2
x
|
9.6
x
|
8.86
x
|
8.14
x
|
EV / FCF
|
26.8
x
|
15.9
x
|
11.7
x
|
8.44
x
|
17.6
x
|
22.1
x
|
18.1
x
|
16.2
x
|
FCF Yield
|
3.74%
|
6.31%
|
8.55%
|
11.8%
|
5.68%
|
4.53%
|
5.53%
|
6.19%
|
Price to Book
|
2.37
x
|
2.55
x
|
2.87
x
|
2.14
x
|
2.17
x
|
1.6
x
|
1.58
x
|
1.55
x
|
Nbr of stocks (in thousands)
|
473,945
|
475,174
|
477,907
|
471,771
|
470,806
|
480,404
|
-
|
-
|
Reference price
2 |
27.10
|
30.43
|
38.40
|
33.01
|
35.57
|
26.30
|
26.30
|
26.30
|
Announcement Date
|
8/19/19
|
8/19/20
|
8/23/21
|
8/23/22
|
8/16/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6,134
|
6,832
|
8,752
|
9,340
|
8,169
|
8,835
|
9,338
|
9,732
|
EBITDA
1 |
1,061
|
1,425
|
2,560
|
2,830
|
1,708
|
1,599
|
1,724
|
1,864
|
EBIT
1 |
787.7
|
819.2
|
1,918
|
2,155
|
1,005
|
824.8
|
915.8
|
1,029
|
Operating Margin
|
12.84%
|
11.99%
|
21.92%
|
23.07%
|
12.3%
|
9.34%
|
9.81%
|
10.57%
|
Earnings before Tax (EBT)
1 |
722.3
|
699.1
|
1,829
|
2,077
|
931.2
|
698.1
|
781.5
|
921.6
|
Net income
1 |
549.7
|
527.7
|
1,315
|
1,461
|
685
|
491.7
|
561.8
|
649.5
|
Net margin
|
8.96%
|
7.72%
|
15.03%
|
15.64%
|
8.39%
|
5.57%
|
6.02%
|
6.67%
|
EPS
2 |
1.221
|
1.106
|
2.731
|
3.025
|
1.450
|
1.028
|
1.158
|
1.351
|
Free Cash Flow
1 |
565.7
|
1,125
|
1,769
|
1,939
|
1,082
|
694.8
|
845.6
|
938.7
|
FCF margin
|
9.22%
|
16.47%
|
20.22%
|
20.76%
|
13.24%
|
7.86%
|
9.06%
|
9.64%
|
FCF Conversion (EBITDA)
|
53.33%
|
78.97%
|
69.12%
|
68.5%
|
63.36%
|
43.44%
|
49.04%
|
50.35%
|
FCF Conversion (Net income)
|
102.91%
|
213.24%
|
134.54%
|
132.75%
|
157.95%
|
141.29%
|
150.51%
|
144.52%
|
Dividend per Share
2 |
0.8400
|
0.8500
|
0.9100
|
1.000
|
1.040
|
0.9410
|
0.9563
|
1.043
|
Announcement Date
|
8/19/19
|
8/19/20
|
8/23/21
|
8/23/22
|
8/16/23
|
-
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
3,344
|
3,488
|
4,432
|
4,319
|
4,757
|
4,584
|
4,082
|
4,087
|
4,306
|
4,594
|
4,592
|
4,847
|
EBITDA
1 |
548
|
877.1
|
1,307
|
1,253
|
1,540
|
1,291
|
920.2
|
787.3
|
736.7
|
865.4
|
811
|
902
|
EBIT
1 |
399.9
|
419.3
|
993.8
|
924.4
|
1,208
|
947
|
574.6
|
430
|
353
|
462
|
404
|
478
|
Operating Margin
|
11.96%
|
12.02%
|
22.42%
|
21.4%
|
25.39%
|
20.66%
|
14.07%
|
10.52%
|
8.2%
|
10.06%
|
8.8%
|
9.86%
|
Earnings before Tax (EBT)
1 |
347.4
|
-
|
944
|
884.6
|
1,168
|
908.7
|
536.9
|
394.3
|
300
|
389
|
326
|
402
|
Net income
1 |
256
|
271.7
|
677.6
|
637.4
|
827.7
|
632.9
|
382.4
|
302.6
|
202.3
|
271.5
|
220
|
282
|
Net margin
|
7.66%
|
7.79%
|
15.29%
|
14.76%
|
17.4%
|
13.81%
|
9.37%
|
7.41%
|
4.7%
|
5.91%
|
4.79%
|
5.82%
|
EPS
2 |
0.5370
|
0.5690
|
1.409
|
1.322
|
1.708
|
1.317
|
0.8090
|
0.6410
|
0.4260
|
0.5647
|
0.4645
|
0.5600
|
Dividend per Share
2 |
0.3400
|
0.5100
|
0.3600
|
0.5500
|
0.4000
|
0.6000
|
0.4200
|
0.6200
|
0.4300
|
0.6510
|
0.4520
|
0.6800
|
Announcement Date
|
2/18/20
|
8/19/20
|
2/17/21
|
8/23/21
|
2/20/22
|
8/23/22
|
2/15/23
|
8/16/23
|
2/19/24
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,299
|
3,386
|
2,335
|
797
|
2,302
|
2,717
|
2,648
|
2,539
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.167
x
|
2.376
x
|
0.9122
x
|
0.2816
x
|
1.348
x
|
1.699
x
|
1.536
x
|
1.362
x
|
Free Cash Flow
1 |
566
|
1,125
|
1,769
|
1,939
|
1,082
|
695
|
846
|
939
|
ROE (net income / shareholders' equity)
|
11.5%
|
9.46%
|
22%
|
21.4%
|
9.05%
|
6.21%
|
6.94%
|
7.86%
|
ROA (Net income/ Total Assets)
|
6.05%
|
4.78%
|
11%
|
12%
|
5.36%
|
3.8%
|
4.33%
|
4.81%
|
Assets
1 |
9,080
|
11,044
|
11,944
|
12,156
|
12,776
|
12,929
|
12,968
|
13,499
|
Book Value Per Share
2 |
11.40
|
11.90
|
13.40
|
15.40
|
16.40
|
16.50
|
16.60
|
17.00
|
Cash Flow per Share
2 |
1.880
|
2.850
|
4.240
|
4.610
|
3.110
|
2.330
|
2.690
|
2.900
|
Capex
1 |
282
|
235
|
274
|
287
|
389
|
500
|
516
|
547
|
Capex / Sales
|
4.59%
|
3.44%
|
3.13%
|
3.07%
|
4.76%
|
5.66%
|
5.52%
|
5.62%
|
Announcement Date
|
8/19/19
|
8/19/20
|
8/23/21
|
8/23/22
|
8/16/23
|
-
|
-
|
-
|
Last Close Price
26.3
AUD Average target price
26.9
AUD Spread / Average Target +2.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +76.62% | 4.54B | | +14.48% | 2.94B | | -3.15% | 2.65B | | -8.59% | 1.89B | | -53.65% | 1.86B | | -13.64% | 1.56B | | +22.37% | 1.26B | | -46.33% | 1.09B | | +16.04% | 963M |
Medical & Diagnostic Laboratories
|